One-Year Phase II Data Presented at the 2010 ACTRIMS Meeting PARIS, June 7, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

This Release is Intended for UK Media Only FRIMLEY, England, June 5, 2010 -

Great Environmental Gala in Rwanda on TV Worldwide KIGALI, Rwanda, June 5, 2010 - High-ranking UN VIPs, well-known environmental advocates, a glamorous party and above all: the best environmental projects in the world - that was the ENERGY GLOBE Gala - Rwanda 2010. This year the number one environmental gala served as the official inaugural event for the UN World Environment Day (WED) and at the same time demonstrated just how important the ENERGY GLOBE has become.

Leading Glass and Aluminium Manufacturer Streamlines Integration with Oracle E-Business Suite, Legacy Systems and Third Party Applications using Oracle SOA Suite 11g